Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941826 | 0.88 | PRMT5 (0.36) | TP53MAPTALDH1A1KDM4ECSF1R | |
| SCHEMBL9975763 | 0.88 | AXL (0.41) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL10323907 | 0.88 | KCNH2 (0.36) | NPC1RAB9ASMN1; SMN2TP53NFKB1 | |
| SCHEMBL10325080 | 0.87 | MAPT (0.33) | TP53MAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL10325287 | 0.87 | NAMPT (0.34) | NPC1RAB9ASMN1; SMN2MAPTAURKA | |
| SCHEMBL9975722 | 0.86 | GAA (0.41) | TP53MAPTALDH1A1HTTHPGD | |
| SCHEMBL10325146 | 0.86 | PRMT5 (0.37) | TP53MAPTL3MBTL1ACKR3CSF1R | |
| SCHEMBL16203336 | 0.86 | MAPT (0.33) | TP53MAPTL3MBTL1CSF1RAURKA | |
| SCHEMBL9975652 | 0.86 | KIT (0.37) | MAPTALDH1A1KDM4E | |
| SCHEMBL9975808 | 0.85 | RAB9A (0.43) | NPC1RAB9ASMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | POLR2E, POLR2H, GTF3C3 | NPC1 353/4885RAB9A 3932/4885SMN1; SMN2 4863/4885 |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | NPC1 658/4885RAB9A 2683/4885SMN1; SMN2 4781/4885 |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2E, POLR2H, GTF3C3 | NPC1 353/4885RAB9A 3932/4885SMN1; SMN2 4863/4885 |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | POLR2E, POLR2H, GTF3C3 | NPC1 353/4885RAB9A 3932/4885SMN1; SMN2 4863/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | NPC1 658/4885RAB9A 2683/4885SMN1; SMN2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.